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Abstract
Background: Ifosfamide, an alkylating agent used widely in the treatment of childhood malignancy, can cause
many side effects including a proximal tubulopathy. Studies suggest that aminoaciduria is seen most commonly
of all the biochemical abnormalities of ifosfamide-induced tubulopathy. A recent systematic review has found a
paucity of data regarding the value of early markers indicating clinically significant tubulopathy. We undertook a
pilot study to determine the feasibility of examining whether patients can be risk-stratified on the basis of aminoaciduria
for the development of future significant ifosfamide-induced tubulopathy, to allow the evolution of appropriate
follow-up strategies. We also aimed to define accrual rates, costs and clinical demands for a future larger study.
Methods: This observational study recruited 21 patients from the Leeds Paediatric Oncology service. The
medical notes of each patient were reviewed for demographic and clinical data. Simultaneous samples of
blood and urine were obtained.
Results: The investigations in the feasibility study were acceptable to patients and were minimally
demanding on
both clinical and laboratory staff. Financially, the cost per patient was minimal. This study was not powered
to detect significant associations with TmP/GFR (ratio of renal tubular maximum reabsorption rate of
phosphate to glomerular filtration rate), growth and electrolyte supplementation. However, all patients with
minimal aminoaciduria (≤2 elevated urinary amino acids) had normal TmP/GFR and no need for electrolyte
supplementation.
Conclusions: This pilot study has shown that a larger study is feasible and may provide clinically useful data
to change current practice. This should aim to establish whether the number of abnormal amino acids or the
degree of abnormality is most significant in predicting clinically significant proximal tubulopathy.
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Background
Ifosfamide is an alkylating agent that is used widely for
the treatment of malignancies, including those seen in
children. Ifosfamide can cause many immediate and
some long-lasting side effects, including a proximal tubu-
lopathy and renal impairment [1]. The proximal tubulopa-
thy results in phosphaturia, glycosuria, aminoaciduria,
hypophosphataemia, hypokalaemia and a hyperchloraemic
metabolic acidosis [2]. Clinically, there is a spectrum of
proximal renal tubular disease ranging from clinically in-
significant glycosuria and mild phosphaturia to a more se-
vere generalised tubulopathy which is clinically significant
and requires increased fluid intake, along with potassium,
phosphate and bicarbonate supplementation [3]. If unrec-
ognised, severe tubulopathy leads to poor growth, general
malaise and metabolic bone disease which can result in
pathological fractures [4, 5]. The majority of patients will
develop a temporary acute proximal tubulopathy whilst
receiving ifosfamide. However, the prevalence of long-
term ifosfamide-induced tubulopathy has not yet been
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clearly defined, with estimates of 6–46 % of patients who
have received ifosfamide as treatment for cancer [6].
Current long-term follow-up programmes aimed to
detect renal damage in children who have received ifos-
famide vary. Studies suggest that aminoaciduria is the
most frequently detected abnormality in tubular dys-
function and hence may be a good early predictor of
long-term ifosfamide-induced tubulopathy [7]. The pres-
ence of aminoaciduria is due to an impairment of the
mechanisms which would normally result in the re-
absorption of amino acids from the filtrate in the prox-
imal tubule [3].
A recent systematic review performed by this group
has looked at the accuracy and utility of early markers of
ifosfamide-induced proximal tubulopathy [6]. This re-
view found a general paucity of data in this area. The
evidence that is available suggests that low levels of ami-
noaciduria indicate a low risk of developing a clinically
significant tubulopathy. This review also found that
urinary β2 macroglobulin might be useful in a similar
way, with low levels suggesting a low risk of significant
tubulopathy and high levels identifying patients at higher
risk who require more intense follow-up. However, the
evidence for the use of urinary β2 microglobulin is even
scarcer than that for aminoaciduria.
We undertook a pilot study to determine the feasibility
of performing a larger more definitive study into this
question. Specifically, we aimed to determine the patient
accrual rate, to monitor data quality of samples when
processing the results in the laboratory, to determine the
costs associated with these extra investigations and to
assess the extra demand on clinical and laboratory staff.
Finally, we hoped to determine whether there is an indi-
cation that generalised aminoaciduria is a good negative
predictive marker for long-term tubulopathy so as to
justify the larger future study.
The final study would aim to establish whether pa-
tients can be risk-stratified for the likelihood of future
significant ifosfamide-induced tubulopathy. This would
then allow more tailored follow-up strategies for patients
deemed to be at risk of developing a clinically significant
tubulopathy following completion of chemotherapy. This
may improve the speed of detection of at-risk patients
whilst simultaneously reducing the burden of investiga-
tion for those patients who are at low risk of developing
this complication of their treatment.
Methods
This study was assessed and approved by an NHS Re-
search Ethics Committee (NHS REC Leeds West Ref 10/
H1307/22) prior to commencement. Leeds Teaching Hos-
pitals NHS Trust is a tertiary referral hospital and pro-
vides care for approximately 110 new children and young
people diagnosed with malignancy per year. All patients
within the Regional Oncology Service in Leeds who had
completed ifosfamide chemotherapy between 2003 and
2012, and were between 3 months and 5 years from com-
pleting treatment, were identified using local records. This
was considered to be adequate to assess the feasibility
within the clinical environment and the laboratory along
with the potential uptake rate by patients. These children
had been treated according to standard national chemo-
therapy protocols for their disease. The only exclusion cri-
terion was the presence of renal impairment or
tubulopathy prior to the commencement of treatment
with ifosfamide. Information leaflets were sent to identi-
fied patients through the post, and patients were then
approached at their next clinic appointment to determine
their decision regarding participation. All included pa-
tients provided written informed consent to participate.
After obtaining consent, the medical notes of each pa-
tient were reviewed for the demographic and clinical data
included in Table 1. Simultaneous samples of blood and
urine were obtained, and investigations as per Table 2
were performed during their next, routinely planned,
clinic appointment. Height and weight were measured
using calibrated equipment within the clinic, by staff regu-
larly trained in the taking of these measurements. Growth
velocity was measured for the year before study enroll-
ment and was compared to Tanner and Davies charts [8].
For each patient, the degree of aminoaciduria was clas-
sified as normal (≤2 amino acids above the normal
range), mild (3–7 amino acids above the normal range)
or generalised (≥8 amino acids above the normal range)
[7]. Any patients who were detected to have significant
aminoaciduria and/or abnormal serum electrolytes or bi-
carbonate were contacted and commenced on supple-
mentation under the direction of the paediatric
nephrology team. The definition of proximal tubulopa-
thy was a reduced TmP/GFR (ratio of renal tubular
maximum reabsorption rate of phosphate to glomerular
filtration rate) below the normal range for age, reduced
growth velocity ≤3rd centile for age or need for electro-
lyte supplementation.
Table 1 Demographic and clinical data collected
Age (years), sex and ethnicity of patient
Date of data collection
Underlying diagnosis
Cumulative dose of ifosfamide received (g/m2)
Other chemotherapeutic agents used




Growth velocity in year prior to investigations (cm/year)
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Statistical analysis
Basic descriptive analysis was performed on the demo-
graphic data of the patients. The degree of aminoacid-
uria was analysed against electrolyte supplementation,
growth velocity ≤3rd centile for age and TmP/GFR less
than the normal range using the chi-square test. Spear-
son’s rank correlation coefficient was calculated for the
relationship between number of raised amino acids and
TmP/GFR. Analysis was performed using SPSS software
(IBM, version 22, Armonk, NY). A p value of 0.05 was
defined as the threshold for significance, and 95 % confi-
dence intervals are provided where appropriate. It is
recognised that these results are preliminary given the
small sample size.
In order to determine the feasibility of a larger study,
we also collected data on the costs for each patient, the
steps involved in processing results and the practical
challenges encountered through the performance of this
pilot study. The demands on clinical and lab staff were
assessed through ongoing discussion with the involved
parties. In particular, the laboratory staff time involved
in the interpretation of chromatography was assessed so
as to establish the demands for this part of the service.
Results
Information leaflets were sent to 39 patients, of these, 24
consented to be included in the study. One patient con-
sented to enter the study but did not complete the in-
vestigations required. Two patients were excluded as
their samples could not be processed for technical rea-
sons. Full study data was available for 21 patients.
Feasibility of the full study
Overall accrual to the study was 21 of 39 (54 %) of in-
vited patients. Originally, we had intended to measure
urinary β2 microglobulin, but the requirement of special
preparation of patients to ensure alkaline urine was con-
sidered to be inappropriate for routine use and therefore
was not performed.
The data collected was generally of good quality with
fewer than 10 % of samples unable to be processed. Not-
ably, the most poorly recorded item of data was the
urine dipstick (only available for 12 of 21 patients); it is
unclear whether this was not performed or simply not
documented (see Fig. 1)
Reports from laboratory staff are that there was min-
imal disruption to the usual service as the number of pa-
tients involved was small. Each sample requires the
following steps to be taken. Firstly, sample preparation
including precipitation, spinning, loading and placing
onto analyser, preparing the analyser and inputting sam-
ples to software must take place. On average, this takes
30 min for six samples. Then the sample is run through
the analyser. This takes 3 h. Next, the quantitative re-
sults must be evaluated and verified. A senior member
of staff familiar with chromatography has to review all
the peaks in each chromatogram and ensure that the
quantification parameters are correct. Finally, the data
must then be manually entered into the reporting sys-
tem. These final processes take 20 to 30 min per sample.
There were some problems within the laboratory be-
cause TmP/GFR is performed so infrequently that the
staff booking the samples into the laboratory failed to
recognise what tests were required for 6 of the 21 sam-
ples. This resulted in laboratory staff having to spend
extra time chasing up results so that the TmP/GFR
could be derived [5].
The cost of the study investigations was £35.75 per pa-
tient. Administration costs were included within the
usual departmental budget. They amounted to less than
£100 for all patients.
Clinical results
The demographic characteristics of the study patients
are detailed in Table 3. The range of underlying diagno-
ses is seen in Fig. 2.
Of the 21 patients included in the study, 7 (33 %) had
normal, 5 (24 %) had mild and 9 (43 %) had generalised
aminoaciduria. The degree of aminoaciduria did not
show statistically significant association with the need
for electrolyte supplementation (p = 0.096), growth vel-
ocity ≤3rd centile for age (p = 0.92) or TmP/GFR less
than the normal range (p = 0.24).
No patients with no or mild aminoaciduria required
electrolyte supplementation (95 % confidence interval
(CI) 0–35 % for no aminoaciduria, 95 % CI 0–43 % for
mild aminoaciduria); 33 % of patients with generalised
aminoaciduria required electrolyte supplementation
(95 % CI for proportion 12–65 %). When growth vel-
ocity ≤3rd centile for age was assessed, 29 % (95 % CI
8–64 %) of children with no aminoaciduria, 40 % (95 % CI
12–77 %) of children with mild aminoaciduria and 33 %
(95 % CI 12–65 %) of children with generalised aminoac-
iduria had poor growth. No patients (95 % CI 0–35 %)
with no aminoaciduria had low TmP/GFR; 20 % (95 % CI
4–62 %) of children with mild aminoaciduria and 33 %
Table 2 Investigations performed




Urinalysis for proteinuria and glycosuria
Ratio of renal tubular maximum reabsorption rate of phosphate
to glomerular filtration rate (TMP/GFR)
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(95 % CI 12–65 %) of children with generalised aminoac-
iduria had low TmP/GFR.
However, when examining the raw data looking at the
need for electrolyte supplement and TmP/GFR, the
trend suggests that aminoaciduria does indicate abnor-
malities in these areas which this study is not powered
to detect. Indeed, only one patient of the four patients
with decreased TmP/GFR did not have generalised ami-
noaciduria, having only six raised urinary amino acids
but did have three other amino acids excreted at the
upper limit of the normal range. He also had proteinuria
and glycosuria on urine dipstick but did not require
electrolyte supplementation. One patient with low TmP/
GFR required electrolyte supplementation with phos-
phate and calcium.
Notably, patients with minimal aminoaciduria (≤2
amino acids above the normal range) had no need for
electrolyte supplementation and normal TmP/GFR.
The scatter graph in Fig. 3 demonstrates the correl-
ation between aminoaciduria and TmP/GFR. The
Spearman’s rank correlation coefficient for this rela-
tionship is −0.396 (p = 0.075), which suggests that an
increased number of abnormal amino acids may be as-
sociated with lower TmP/GFR.
Six children had received cyclophosphamide within
their chemotherapeutic regimes. Two of these had gen-
eralised aminoaciduria, of which one had low TmP/GFR
and low growth velocity, two had mild aminoaciduria, of
which one had low TmP/GFR and two had normal levels
of amino acid excretion, of which one had low growth
velocity. None of these children required electrolyte
supplementation.
Three children received platinum chemotherapy. One,
who had also received cyclophosphamide, had general-
ised aminoaciduria, low TmP/GFR and low growth vel-
ocity. One had mild aminoaciduria, normal TmP/GFR
and low growth velocity. The final child had normal




This protocol was generally well accepted by patients as
it required little extra investigation, with only one add-
itional blood and urine test beyond current surveillance.
The study was also minimally demanding on both clin-
ical and laboratory staff. Financially, the cost per patient
was minimal. The omissions in data could be reduced by
creating structured follow-up schedules which staff
could easily follow within the clinic. Over time, this
would become part of standard procedures and therefore
be less likely to be forgotten or undocumented.
Clinical results
The data from these patients showed no significant cor-
relation between aminoaciduria and need for electrolyte
supplementation, growth velocity ≤3rd centile for age or
TmP/GFR less than the normal range. However, the raw
data does suggest that generalised aminoaciduria trends
towards a need for electrolyte supplementation and also
Fig. 1 Investigations performed
Table 3 Demographic characteristics of patients
Male: female 10:11
Median age 10.9 years (range 4–19 years)
Ethnicity 19 white British1 Indian1 ‘any
other mixed background’
Mean cumulative dose of
ifosfamide (g/m2)
61 (range 16.5–102)
Time between last dose of ifosfamide
and sample collection (months)
Median 25 (range 3–107)
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a lower TmP/GFR. The finding that patients with minimal
aminoaciduria had no need for electrolyte supplementa-
tion and had normal TmP/GFR needs to be confirmed, as
this may have significant clinical applications.
Comments on limitations and generalisability of the
study
This study was limited by the number of patients in-
volved, which was a result of being run in a single
centre. This reduced the power of the statistical calcula-
tions such that significance was not met. The larger
study from this pilot should be designed to overcome
this problem. Furthermore, this study had a majority of
White British patients and therefore may not be
generalizable to those from Black and ethnic minority
groups. The main study should aim to increase the num-
ber of patients recruited from this population.
Finally, although we have described the use of other
nephrotoxic chemotherapeutic agents, given the small
numbers of patients involved, no conclusions can be
drawn from this. Consideration should be given to the
role of these drugs and other nephrotoxic medications
used in combination with ifosfamide within future
studies.
The feasibility of this study has been established, with
minimal clinical or laboratory issues. However, generalis-
ing this practice to other centres will need consideration
of local systems and protocols. Establishing a multi-
centre study will hold significant challenges that have
not been explored by this pilot, including centralisation
of data, data storage, selection of patients across centres
and other costs. The future study should also aim to
have firm criteria for the use of electrolyte supplementa-
tion so as to ensure consistent findings and therefore
outcomes across all patients. Furthermore, the future
study should aim to take into account the potential
changes in tubulopathy over time and may aim to iden-
tify the most appropriate time point for screening. Previ-
ous works by Rossi et al. and Skinner may inform this
work [7, 9].
When considered in light of the recent systematic re-
view, the prevalence of generalised aminoaciduria within
Fig. 2 Underlying diagnoses
Fig. 3 Correlation between aminoaciduria and TmP/GFR
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this sample was within the range previously reported [6].
In particular, we can compare this study with that done
by Rossi et al., as measuring similar variables [7]. We
found 43 % of patients to have generalised aminoacid-
uria compared with 28 % in Rossi’s sample. Meanwhile,
19 % of patients we studied had a TmP/GFR below the
normal range, whilst Rossi et al. reported 17.3 % had se-
vere impairment of phosphate reabsorption. The two
studies are different, in that we measured only one epi-
sode of data for each patient, compared with multiple
data points in the work of Rossi et al. We also had dif-
ferent periods of follow-up per patient and this may re-
flect a different phase in the development of proximal
tubulopathy following ifosfamide. Rossi et al. also found
that the absence of generalised aminoaciduria was not
associated with significant tubulopathy.
Overall, the suggestion from this study is that the ab-
sence of generalised aminoaciduria is a good negative
predictive marker for long-term tubulopathy.
Conclusions
This pilot study has shown that the intended main study
is feasible and may provide clinically useful data with
potential to change current practice. A power calculation
has been completed for the proposed main study. This
calculation was based on a cohort of 100 patients and a
7 % prevalence of a clinically significant tubulopathy
(proposed primary outcome measure for main study).
With a sensitivity of 91 % and a specificity of 75 %, we
estimate that a population of 180 patients will be needed
to provide an adequately powered study. We estimate
that this may take 3 years if performed as a multi-
centred trial of ten centres with 12 new eligible patients
seen per year per centre (with 54 % accrual). Future
studies should aim to establish whether the number of
abnormal amino acids or the degree of abnormality is
most significant in predicting long-term clinically signifi-
cant proximal tubulopathy.
Furthermore, other specialties may wish to investigate
the use of aminoaciduria as a screening tool for other
patients at risk of drug-induced tubulopathy, for ex-
ample those treated with sodium valproate for seizures.
Abbreviation
TmP/GFR: ratio of renal tubular maximum reabsorption rate of phosphate to
glomerular filtration rate.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
JEM: M performed data collection, carried out the initial analyses, drafted the
initial manuscript and approved the final manuscript as submitted. KM: M
conceptualised and designed the study, critically reviewed the manuscript
and approved the final manuscript as submitted. KST: T was involved in the
design of the study, reviewed and revised the manuscript and approved the
final manuscript as submitted. MH: H was involved in the design of the
study, was responsible for the amino acid analysis and interpretation,
contributed ideas to the write-up and approved the final manuscript as
submitted. SP: P was involved in the design of the study, assisted in data
collection, critically reviewed the manuscript and approved the final manuscript
as submitted. RSP: P was involved in the design of the study and collection of
the data, supervised the analysis of the data, and revised and approved the final
manuscript as submitted.
Author details
1Department of Paediatric Oncology, Leeds Teaching Hospitals NHS Trust,
Leeds, UK. 2Centre for Reviews and Dissemination, University of York, Leeds,
UK. 3Department of Paediatric Nephrology, Royal Belfast Hospital for Sick
Children, Leeds, UK. 4Department of Paediatric Nephrology, Leeds Teaching
Hospitals NHS Trust, Leeds, UK. 5Department of Biochemical Genetics, Leeds
Teaching Hospitals NHS Trust, Leeds, UK.
Received: 13 May 2015 Accepted: 3 December 2015
References
1. Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, et al. Ifosfamide
nephrotoxicity in pediatric cancer patients. Pediatr Nephrol Berl Ger. 2001;
16:796–9.
2. Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L,
et al. A prospective evaluation of ifosfamide-related nephrotoxicity in
children and young adults. Cancer. 1995;76:2557–64.
3. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol.
2003;41:190–7. doi:10.1002/mpo.10336.
4. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up
of ifosfamide renal toxicity in children treated for malignant mesenchymal
tumors: an International Society of Pediatric Oncology report. J Clin Oncol
Off J Am Soc Clin Oncol. 1991;9:2177–82.
5. Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after
ifosfamide treatment in children: a UKCCSG Late Effects Group study.
Br J Cancer. 2000;82:1636–45. doi:10.1054/bjoc.2000.1214.
6. Phillips RS, Tyerman K, Al-Kassim MI, Picton S. A systematic review of the
accuracy and utility of early markers of ifosfamide-induced proximal
tubulopathy in survivors of childhood cancers. Pediatr Hematol-Oncol.
2008;25:107–13. doi:10.1080/08880010701885276.
7. Rossi R, Pleyer J, Schäfers P, Kuhn N, Kleta R, Deufel T, et al. Development of
ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
Med Pediatr Oncol. 1999;32:177–82.
8. Tanner JM, Davies PS. Clinical longitudinal standards for height and height
velocity for North American children. J Pediatr. 1985;107:317–29.
9. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ. Glomerular
toxicity persists 10 years after ifosfamide treatment in childhood and is not
predictable by age or dose. Pediatr Blood Cancer. 2010;54:983–9. doi:10.
1002/pbc.22364.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Morgan et al. Pilot and Feasibility Studies  (2016) 2:4 Page 6 of 6
